Aristotle Capital Boston LLC Sells 64,071 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Aristotle Capital Boston LLC cut its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 9.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 583,474 shares of the company's stock after selling 64,071 shares during the quarter. Prestige Consumer Healthcare makes up approximately 1.7% of Aristotle Capital Boston LLC's portfolio, making the stock its 14th largest holding. Aristotle Capital Boston LLC owned 1.18% of Prestige Consumer Healthcare worth $45,563,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PBH. Barclays PLC increased its holdings in shares of Prestige Consumer Healthcare by 346.3% in the third quarter. Barclays PLC now owns 92,444 shares of the company's stock worth $6,665,000 after purchasing an additional 71,730 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 4.3% during the 3rd quarter. Franklin Resources Inc. now owns 21,585 shares of the company's stock worth $1,513,000 after acquiring an additional 894 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Prestige Consumer Healthcare by 3.2% in the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company's stock valued at $19,630,000 after acquiring an additional 8,533 shares during the last quarter. GAMMA Investing LLC increased its stake in Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock valued at $108,000 after acquiring an additional 220 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in Prestige Consumer Healthcare by 3.4% during the fourth quarter. Nordea Investment Management AB now owns 90,693 shares of the company's stock valued at $7,066,000 after purchasing an additional 2,985 shares in the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Performance

PBH traded up $5.43 during midday trading on Thursday, reaching $86.84. The company had a trading volume of 245,010 shares, compared to its average volume of 293,365. The business has a 50-day moving average of $83.08 and a two-hundred day moving average of $81.11. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare Inc. has a 1 year low of $62.35 and a 1 year high of $90.04. The company has a market cap of $4.30 billion, a P/E ratio of 20.34, a P/E/G ratio of 2.69 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. During the same period in the prior year, the business earned $1.02 EPS. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Oppenheimer boosted their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Royal Bank of Canada boosted their price target on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a report on Friday, March 21st. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. DA Davidson lifted their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Canaccord Genuity Group raised their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $93.33.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares of the company's stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by insiders.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.